XOMA Announces the Sale of Its Manufacturing Facilities to Agenus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
XOMA (XOMA) Uses License Deals and Restructuring to Extend Runway to 2017; Piper Jaffray Remains Neutral
November 6, 2015 10:35 AM ESTPiper Jaffray reiterated a Neutral rating on XOMA, Ltd. (NASDAQ: XOMA), and raised the price target to $1.80 (from $1.50), following the company's 3Q earnings report. XOMA ended 3Q:15 with $32 million. The company subsequently received $37 million from Novartis for TGF-beta upfront and $5 million from Agenus for an... More
Agenus (AGEN) to Acquire XOMA's (XOMA) Biologics Manufacturing Facilities
November 5, 2015 4:11 PM ESTXOMA (NASDAQ: XOMA) announced today it has agreed to sell its biologics manufacturing facilities, equipment, and associated real estate to Agenus Inc. (Nasdaq: AGEN). The transaction is expected to close in December 2015. In conjunction with the transaction, Agenus will offer employment to a select team of XOMA employees currently operating the facilities and may provide... More
